Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The Mitogen-Activated Protein Kinase (MAPK) pathway involves RAS, RAF, MEK, and ERK.
• RAS proteins are frequently mutated, driving cancer development.
• KRAS, an isoform of RAS, has splice variants K-Ras4A and K-Ras4B, often mutated in cancer.

Purpose of the Study:

• To elucidate the mechanism of the RAS protein complex and the movement of switches I and II.
• To review recent developments in synthetic RAS inhibitors.
• To discuss challenges and future directions in developing novel RAS inhibitors.

Main Methods:

• Literature review of synthetic RAS inhibitors.
• Analysis of RAS protein complex mechanisms.
• Examination of switch I and II movements in RAS.

Main Results:

• Detailed elucidation of RAS protein complex mechanisms.
• Overview of current FDA-approved RAS inhibitors (sotorasib, adagrasib) and those in clinical trials.
• Identification of unique properties and importance of synthetic RAS inhibitors.

Conclusions:

• Understanding RAS mechanisms is crucial for cancer therapy.
• Synthetic RAS inhibitors show promise but face development challenges.
• This review provides insights for designing novel RAS inhibitors for cancer treatment.